Glenmark Pharmaceuticals Ltd has secured final approval from the USFDA for its generic brimonidine tartrate and timolol maleate ophthalmic solution, used to treat increased eye pressure from glaucoma or other conditions. The solution, with strengths of 0.2% brimonidine tartrate and 0.5% timolol maleate, is deemed bioequivalent and therapeutically equivalent to AbbVie Inc.’s Combigan ophthalmic solution. Glenmark’s version will be distributed in the US through Glenmark Pharmaceuticals Inc, USA. With Combigan achieving annual sales of about USD 290 million, this approval marks a significant milestone for Glenmark in the lucrative US market.
Glenmark Pharmaceuticals Receives Final FDA Approval for Generic Eye Treatment
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2024/05/18102656/1700098009-925-ezgif.com-avif-to-jpg-converter.jpg)